• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Final spring practicum 6 apr10
 

Final spring practicum 6 apr10

on

  • 260 views

 

Statistics

Views

Total Views
260
Views on SlideShare
258
Embed Views
2

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 2

http://www.slideshare.net 2

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Final spring practicum 6 apr10 Final spring practicum 6 apr10 Presentation Transcript

    • Business Intelligence Gateway Development Project A Beta-Test of Drug Discovery Opportunity Identification
    • Goal: To delineate drug discovery opportunities in a field of interest to multiple pharmaceutical companies utilizing structured data searching software for the Drug Discovery Center of Innovation and identify Chinese gateways for The Hamner Institute Field: Oncology – Pathways that regulate the fate of cancer stem cells
    • Objectives:
      • Identify stem cell/oncology research conducted since 2008
      • Identify researchers in China that are working:
        • on novel and unique targets
        • on novel or unique compound regulators
        • on novel or unique models/assays
        • with NC University investigators
        • with companies interested in the field and identify those companies
      • Identify researchers in the U.S. that are working:
        • on novel and unique targets
        • on novel or unique compound regulators
        • on novel or unique models/assays
      • Quickly identify list of new or unique targets, drug candidates, and models or assays of potential interest to pharmaceutical companies that could form the basis for future drug discovery and development partnerships
    • What is the value of VantagePoint? 1 day 1 second Data Retrieval Speed Fast Slow Company Affiliations Yes No Quick Identification of Targets Yes No Author Networks Yes No Region Specificity 253 1,280,000+ Number of Records Search: “ Novel oncology target” Worldwide 2008-2010 data
    • Process: Team: Pete Geisen, Brian Ridout, Jonathan Dancy Tools: VantagePoint software (version 6.1) Query Journal Databases (Pubmed, Web of Science) Data collection – duplicate identification and removal Data Collection Quality Control Identification of Major Authors in each sub-field (eg. methods, compounds, etc) Discovery of specific novel targets, methods and compounds using pattern recognition Additional Search Terms and QC
    • Search Terms Cancer + Stem Cancer + Stem + Cells Cancer + Progenitor Stem + Cell(s) + Biology Stem + Cell(s) + Targeted + Therapy Subpopulation + Cells Self-renewal Method + Cancer + Isolation Quality Control Cancer + Stem Cancer + Progenitor 13,586 records China USA Unique Targets Novel Compounds Novel Models/ Assays (933 records) (5,843 records) Objectives: Identify research conducted since 2008 Databases Medline (Pubmed) Web of Science Unique Targets Novel Compounds Novel Models/ Assays (37) (8) (15) (247) (67) (89)
    • Objective 2: Identify researchers in China that: (A) Are working on novel or unique targets Initial Query: Records Target: 220 Pathway: 161 Approach: 87 Platform: 5 Avenue: 25 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Target 16
      China records: 933
        • Key Investigators:
        • Tang, Zhao-You
        • Budhu, Anuradha
        • Chen, Dahua
        • Huang, Wei
        • Li, Yan
        • Total Records: 261
        • Key Institutions:
        • Chinese Academy of Science
        • Fudan University
        • Chinese Academy of Med Sci
        • University of Hong Kong
        • Peking Union Med College
        • Shandong University
    • Objective 2: Identify researchers in China that: (B) Are working on novel or unique compounds/regulators Initial Query: Records Compound: 23 Drug: 161 Peptide: 87 Regulator: 96 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Compound 2
      • New Drug 6
      China records: 933
        • Key Investigators:
        • Jin, Ying
        • Pei, Duanqing
        • Wang, Jing
        • Zhang, Baojun
        • Zhang, Yu
        • Total Records: 171
        • Key Institutions:
        • Chinese Academy of Science
        • Peking University
        • Shanghai Jiao Tong University
        • Chinese Academy of Med Sci
        • Huazhong University of Sci
    • Objective 2: Identify researchers in China that: (C) Are working on novel or unique models/assays Initial Query: Records Assay: 181 Model: 186 Construct: 30 System: 193 Therapy: 271 Vaccine: 10 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Model 6
      • New System 3
      • Therapy 7
      China records: 933
        • Key Investigators:
        • Li, Juan
        • Wang, Jing
        • Wang, Liang
        • Xu, Yang
        • Zhang, Jie
        • Total Records: 221
        • Key Institutions:
        • Chinese Academy of Science
        • Shanghai Jiao Tong University
        • Fudan University
        • Peking University
        • Sichuan University
    • China NC Univ Affiliations Author Network UNC Duke Wake Forest Med Univ SC Objective 2: Identify researchers in China that: (D) Are working with NC Investigators
      • UNC
        • Hu-Liang Jia ( Fudan Univ, China): 4 records with UNC
      • Duke (1 record)
      • Wake Forest (1 record)
    • China Corporate Affiliations Author List
      • 19 companies cited, but no author/company networks exist
      • Additionally, no authors are major collaborators with multiple companies
      Objective 2: Identify researchers in China that: (E) have ties to companies working in that field Companies: AmCellGene Co Ltd Appl Biosyst Inc Automated Cell Inc Beijing Vital River Lab Anim Inc Vitalriver Lab Anim Inc Capitalbio Corp Changzhou Qianhong BioPharma Ltd Co Biomed Sci Inc Genentech Inc GlaxoSmithKline Inc Mosaiques Diagnost & Therapeut AG Nitto Denko Tech Co Pentapharm Ltd Rosetta Inpharmat LLC Sequenom Inc Shenzhen Shengjie Biotech Co Ltd Suiseikai Inc Ulm Gemeinnuetzige GmbH Union Stem Cell & Gene Engn Co Ltd Most Cited Authors: Deng, Hongkui Shi, Cheng Yang, Weifeng Most Cited Institutions: Chinese Acad Med Sci Fudan University Peking Union Med Coll Peking University
    • Objective 3: Identify researchers in the US that: (A) Are working on novel or unique targets
        • Key Investigators:
        • Chong, Zhao
        • Maiese, Kenneth
        • Shang, Yan
        • Terzic, Andre
        • Young, Richard
      Initial Query: Records Target: 1585 Pathway: 1202 Approach: 764 Platform: 99 Avenue: 293 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Target 114
      • New Pathway 12
      • New Approach 104
      • New Avenue 16
      US records: 5,843
        • Total Records: 326
        • Key Institutions:
        • Harvard University
        • Johns Hopkins University
        • Stanford University
        • Wayne State University
        • University of Michigan
    • Objective 3: Identify researchers in the US that: (B) Are working on novel or unique compounds/regulators Initial Query: Records Compound: 157 Drug: 1167 Peptide: 274 Regulator: 768 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Compound 12
      • New Drug 36
      • New Peptide 2
      • New Regulator 17
      US records: 5,843
        • Key Investigators:
        • Zhang, Ying
        • Zhao, Jiangbing
        • Anderson, Kenneth
        • Crooks, Peter
        • Farnsworth, Norman
        • Kinghorn, A Douglas
        • Total Records: 210
        • Key Institutions:
        • Harvard University
        • Johns Hopkins University
        • University of Texas, Anderson CC
        • MIT
        • Dana Farber Cancer Institute
    • Objective 3: Identify researchers in the US that: (C) Are working on novel or unique models/assays Initial Query: Records Assay: 626 Model: 1566 Construct: 192 System: 1431 Therapy: 1906 Vaccine: 97 Pattern Recognition: “ Novel”, “New” or “Unique”
        • Records
      • New Assay 7
      • New Model 49
      • New System 11
      • New Therapy 23
      US records: 5,843
        • Key Investigators:
        • Toole, Bryan
        • Barrett, A John
        • Bulte, Jeff
        • Casimiro, Matthew
        • Cotterman, Rebecca
        • Total Records: 183
        • Key Institutions:
        • Harvard University
        • University of Pittsburgh
        • Johns Hopkins University
        • Sloan Kettering Canc Center
        • National Cancer Institute
        • Stanford University
    • Objective 4: List of new targets, compounds, or assays of interest to pharmaceutical companies
        • Targets of interest
          • CCR1
          • Gadd45
          • DKK-1
          • mTOR
          • miR-34
          • KPNA-2
          • ABC-G2
          • NgR
        • Compounds
          • Arylbenzofuran
          • Cardenolides
          • Penicidones
          • Trychostatin
          • Arenicosterol A
        • Assays/Methods
          • Novel NK/T-cell lymphoma mouse model
          • Experimental HCC models
          • Rat mNSC differentiation model